Future research should focus on elucidating the specific mechanisms by which EV markers, such as CD3 and CD56, contribute to PAH complications in SSc, and as therapeutic targets aimed at modulating NK cell-mediated immune responses within affected endothelial microenvironments [27]. Here, NCAM1 is linked to pulmonary arterial hypertension.